Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus

NCT02535689 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
34
Enrollment
NIH
Sponsor class

Conditions

Interventions

Sponsor

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)